Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial

Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial

Trial design: Human papillomavirus infection causes verruca vulgaris. CDK9 inhibitor FIT039 inhibits DNA virus proliferation in animal models. We conducted a multicenter, single-blind, placebo-controlled, randomized phase I/II clinical trial evaluating the safety and efficacy of FIT039 against verru...

Full description

Bibliographic Details
Main Authors: Takashi Nomura, Eriko Sumi, Gyohei Egawa, Saeko Nakajima, Eiko Toichi, Nana Inoue, Mami Shibuya, Natsuko Okamoto, Tsuyoshi Mitsuishi, Ryuji Uozumi, Harue Tada, Takayuki Nakagawa, Nobuhiro Kusuba, Aika Okuno, Chihiro Shimizuhira, Makiko Ishikawa, Shiro Tanaka, Masatoshi Hagiwara, Kenji Kabashima
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:JID Innovations
Online Access:http://www.sciencedirect.com/science/article/pii/S2667026721000266

Internet

http://www.sciencedirect.com/science/article/pii/S2667026721000266

Similar Items